Vaccine protection against Bacillus cereus-mediated respiratory anthrax-like disease in mice

Infection and Immunity

Volumn 81, Issue 3, 2013, Pages 1008-1017

  Oh, So Young ^a,b   Maier, Hannah ^a,b   Schroeder, Jay ^a,b   Richter, G Stefan ^a,b   Elli, Derek ^a,b   Musser, James M ^c   Quenee, Lauriane E ^a,b   Missiakas, Dominique M ^a,b   Schneewinda, Olaf ^a,b  

^a ARGONNE NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; ANTIGEN; PA1 ANTIGEN; PAGA2 ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTHRAX; ARTICLE; BACILLUS CEREUS; BACTERIAL SPORE; BACTERIUM ISOLATION; CONTROLLED STUDY; FEMALE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRULENCE; WILD TYPE;

ANIMALS; BACILLUS CEREUS; BACTERIAL VACCINES; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; MICE; MICE, INBRED C57BL; MUTATION; RESPIRATORY TRACT INFECTIONS;

EID: 84874690344     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01346-12     Document Type: Article

References (60)

1. Miller JM, Hair JG, Hebert M, Hebert L, Roberts FJ, Jr, Weyant RS. 1997. Fulminant bacteremia and pneumonia due to Bacillus cereus. J. Clin. Microbiol. 35:504-507.
2. Hoffmaster AR, Ravel J, Rasko DA, Chapman GD, Chute MD, Marston CK, De BK, Sacchi CT, Fitzgerald C, Mayer LW, Maiden MC, Priest FG, Barker M, Jiang L, Cer RZ, Rilstone J, Peterson SN, Weyant RS, Galloway DR, Read TD, Popovic T, Fraser CM. 2004. Identification of anthrax toxin genes in a Bacillus cereus associated with an illness resembling inhalation anthrax. Proc. Natl. Acad. Sci. U. S. A. 101:8449-8454.
3. Hoffmaster AR, Hill KK, Gee JE, Marston CK, De BK, Popovic T, Sue D, Wilkins PP, Avashia SB, Drumgoole R, Helma CH, Ticknor LO, Okinaka RT, Jackson PJ. 2006. Characterization of Bacillus cereus isolates associated with fatal pneumonias: strains are closely related to Bacillus anthracis and harbor B. anthracis virulence genes. J. Clin. Microbiol. 44: 3352-3360.
4. Wright AM, Beres SB, Consamus EN, Long SW, Flores AR, Barrios R, Richter GS, Oh SY, Garufi G, Maier H, Drews AL, Stockbauer KE, Cernoch P, Schneewind O, Olsen RJ, Musser JM. 2011. Rapidly progressive, fatal, inhalation anthraxlike infection in a human: case report, pathogen genome sequencing, pathology, and coordinated response. Arch. Pathol. Lab. Med. 135:1447-1459.
5. Avashia SB, Riggins WS, Lindley C, Hoffmaster A, Drumgoole R, Nekomoto T, Jackson PJ, Hill K, Williams K, Lehman L, Libal MC, Wilkins PP, Alexander J, Tvaryanas A, Betz T. 2007. Fatal pneumonia among metalworkers due to inhalation exposure to Bacillus cereus containing Bacillus anthracis toxin genes. Clin. Infect. Dis. 44:414-416.
6. Guarner J, Jernigan JA, Shieh WJ, Tatti K, Flannagan LM, Stephens DS, Popovic T, Ashford DA, Perkins BA, Zaki SR; Inhalational Anthrax Pathogology Working Group. 2003. Pathology and pathogenesis of bioterrorism-related inhalational anthrax. Am. J. Pathol. 163:701-709.
7. Jensen GB, Hensen BM, Eilenberg J, Mahillon J. 2003. The hidden lifestyles of Bacillus cereus and relatives. Environ. Microbiol. 5:631-640.
8. Koch R. 1876. Die ätiologie der Milzbrand-Krankheit, begründet auf die Entwicklungsgeschichte des Bacillus anthracis. Beiträge Biol. Pflanz. 2:277-310.
9. Mock M, Fouet A. 2001. Anthrax. Annu. Rev. Microbiol. 55:647-671.
10. Green BD, Battisti L, Koehler TM, Thorne CB, Ivins BE. 1985. Demonstration of a capsule plasmid in Bacillus anthracis. Infect. Immun. 49: 291-297.
11. Uchida I, Hashimoto K, Terakado N. 1986. Virulence and immunogenicity in experimental animals of Bacillus anthracis strains harbouring or lacking 110 MDa and 60 MDa plasmids. J. Gen. Microbiol. 132:557-559.
12. Vodkin M.H., Leppla SH. 1983. Cloning of the protective antigen gene of Bacillus anthracis. Cell 34:693-697.
13. Robertson D.L., Leppla SH. 1986. Molecular cloning and expression in Escherichia coli of the lethal factor gene of Bacillus anthracis. Gene 44:71-78.
14. Leppla SH. 1982. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclin AMP concentrations in eukaryotic cells. Proc. Natl. Acad. Sci. U. S. A. 79:3162-3166.
15. Leppla SH. 2000. Anthrax toxi.n.p 445-472. In Aktories K, Just I (ed), Bacterial protein toxins. Springer, Berlin, Germany.
16. Bradley KA, Mogridge J, Mourez M, Collier RJ, Young JA. 2001. Identification of the cellular receptor for anthrax toxin. Nature 414:225-229.
17. Scobie HM, Rainey GJ, Bradley KA, Young JA. 2003. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc. Natl. Acad. Sci. U. S. A. 100:5170-5174.
18. Milne J, Furlong D, Hanna PC, Wall JS, Collier RJ. 1994. Anthrax protective antigen forms oligomers during intoxication of mammalian cells. J. Biol. Chem. 269:20607-20612.
19. Milne JC, Blanke SR, Hanna PC, Collier RJ. 1995. Protective antigenbinding domain of anthrax lethal factor mediates translocation of a heterologous protein fused to its amino-or carboxy-terminus. Mol. Microbiol. 15:661-666.
20. Young JA, Collier JR. 2007. Anthrax toxin: receptor binding, internalization, pore formation and translocation. Annu. Rev. Biochem. 76:243-265.
21. Preisz H. 1909. Experimentelle Studien Über Virulenz, Empfänglichkeit und Immunität beim Milzbrand. Z. Immun. Forschung 5:341-452.
22. Tomcsik J, Szongott H. 1933.Ü ber ein spezifisches Protein der Kapsel des Milzbrandbazillus. Z. Immun. Forschung 78:86-99.
23. Drysdale M, Heninger S, Hutt J, Chen Y, Lyons CR, Koehler TM. 2005. Capsule synthesis by Bacillus anthracis is required for dissemination in murine inhalation anthrax. EMBO J. 24:221-227.
24. Drobniewski FA. 1993. Bacillus cereus and related species. Clin. Microbiol. Rev. 6:324-338.
25. Bottone EJ. 2010. Bacillus cereus, a volatile pathogen. Clin. Microbiol. Rev. 23:382-398.
26. Stenfors Arnesen LP, Fagerlund A, Granum PE. 2008. From soil to gut: Bacillus cereus and its food poisoning toxins. FEMS Microbiol. Rev. 32: 579-606.
27. Oh SY, Budzik JM, Garufi G, Schneewind O. 2011. Two capsular polysaccharides enable Bacillus cereus G9241 to cause anthrax-like disease. Mol. Microbiol. 79:455-470.
28. Simon NC, Vergis JM, Ebrahimi AV, Ventura CL, O'Brien AD, Barbieri JT. 30 August 2012. Host cell cytotoxicity and cytoskeleton disruption by CerADPr, an ADP-ribosyltransferase of Bacillus cereus G9241. Biochemistry doi:10.1021/bi300692g.
29. Kim HU, Goepfert JM. 1974. A sporulation medium for Bacillus anthracis. J. Appl. Bacteriol. 37:265-267.
30. Leighton TJ, Doi RH. 1971. The stability of messenger ribonucleic acid during sporulation in Bacillus subtilis. J. Biol. Chem. 246:3189-3195.
31. Marraffini LA, Schneewind O. 2006. Targeting proteins to the cell wall of sporulating Bacillus anthracis. Mol. Microbiol. 62:1402-1417.
32. Silo-Suh LA, Lethbridge BJ, Raffel SJ, He H, Clardy J, Handelsman J. 1994. Biological activities of two fungistatic antibiotics produced by Bacillus cereus UW85. Appl. Environ. Microbiol. 60:2023-2030.
33. Garufi G, Wang Y-T, Oh S-Y, Maier H, Missiakas DM, Schneewind O. 2012. Sortase-conjugation generates a capsule vaccine that protects guinea pigs against Bacillus anthracis. Vaccine 30:3435-3444.
34. Grabenstein JD. 2008. Vaccines: countering anthrax: vaccines and immunoglobulins. Clin. Infect. Dis. 46:129-136.
35. Collier RJ, Young JA. 2003. Anthrax toxin. Annu. Rev. Cell Dev. Biol. 19:45-70.
36. Singer DE, Schneerson R, Bautista CT, Rubertone MV, Robbins JB, Taylor DN. 2008. Serum IgG antibody response to the protective antigen (PA) of Bacillus anthracis induced by anthrax vaccine adsorbed (AVA) among U.S. military personnel. Vaccine 26:869-873.
37. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. 1990. Basic local alignment search tool. J. Mol. Biol. 215:403-410.
38. May KR. 1973. The Collison nebulizer: description, performance and applications. J. Aerosol Sci. 4:235-243.
39. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. (Lond.) 27:493-497.
40. Lyons CR, Lovchik J, Hutt J, Lipscomb MF, Wang E, Heninger S, Berliba L, Garrison K. 2004. Murine model of pulmonary anthrax: kinetics of dissemination, histopathology, and mouse strain susceptibility. Infect. Immun. 72:4801-4809.
41. Cote CK, Van Rooijen N, Welkos SL. 2006. Roles of macrophages and neutrophils in the early host response to Bacillus anthracis spores in a mouse model of infection. Infect. Immun. 74:469-480.
42. Cote CK, Rossi CA, Kang AS, Morrow PR, Lee JS, Welkos SL. 2005. The detection of protective antigen (PA) associated with spores of Bacillus anthracis and the effects of anti-PA antibodies on spore germination and macrophage interactions. Microb. Pathog. 38:209-225.
43. Dixon TC, Meselson M, Guillemin J, Hanna PC. 1999. Anthrax. N. Engl. J. Med. 341:815-826.
44. Wilson MK, Vergis JM, Alem F, Palmer JR, Keane-Myers AM, Brahmbhatt TN, Ventura CL, O'Brien AD. 2011. Bacillus cereus G9241 makes anthrax toxin and capsule like highly virulent B. anthracis Ames but behaves like attenuated toxigenic nonencapsulated B. anthracis Sterne in rabbits and mice. Infect. Immun. 79:3012-3019.
45. Chand HS, Drysdale M, Lovchik J, Koehler TM, Lipscomb MF, Lyons CR. 2009. Discriminating virulence mechanisms among Bacillus anthracis strains by using a murine subcutaneous infection model. Infect. Immun. 77:429-435.
46. Heninger S, Drysdale M, Lovchik J, Hutt J, Lipscomb MF, Koehler TM, Lyons CR. 2006. Toxin-deficient mutants of Bacillus anthracis are lethal in a murine model for pulmonary anthrax. Infect. Immun. 74:6067-6074.
47. Smith H, Keppie J, Stanley JL. 1955. The chemical basis of the virulence of Bacillus anthracis. V. The specific toxin produced by Bacillus anthracis in vivo. Br. J. Exp. Pathol. 36:460-472.
48. Crowe SR, Ash LL, Engler RJ, Ballard JD, Harley JB, Farris AD, James JA. 2010. Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge. J. Infect. Dis. 202: 251-260.
49. Welkos SL, Vietri NJ, Gibbs PH. 1993. Non-toxigenic derivatives of the Ames strain of Bacillus anthracis are fully virulent for mice: role of plasmid pXO2 and chromosome in strain-dependent virulence. Microb. Pathog. 14:381-388.
50. Ivins BE, Ezzell JWJ, Jemski J, Hedlund KW, Ristroph JD, Leppla SH. 1986. Immunization studies with attenuated strains of Bacillus anthracis. Infect. Immun. 52:454-458.
51. Pezard C, Berche P, Mock M. 1991. Contribution of individual toxin components to virulence of Bacillus anthracis. Infect. Immun. 59:3472-3477.
52. Sterne M. 1937. Avirulent anthrax vaccine. Onderstepoort J. Vet. Sci. Anim. Ind. 21:41-43.
53. Liu S, Crown D, Miller-Randolph S, Moayeri M, Wang H, Hu H, Morley T, Leppla SH. 2009. Capillary morphogenesis protein-2 is the major receptor mediating lethality of anthrax toxin in vivo. Proc. Natl. Acad. Sci. U. S. A. 106:12424-12429.
54. Liu S, Miller-Randolph S, Crown D, Moayeri M, Sastalla I, Okugawa S, Leppla SH. 2010. Anthrax toxin targeting of myeloid cells through the CMG2 receptor is essential for establishment of Bacillus anthracis infections in mice. Cell Host Microbe 8:455-462.
55. Ivanovics G, Erdös L. 1937. Ein Beitrag zum Wesen der Kaspelsubstanz des Milzbrandbazillus. Z. Immun. Forschung 90:304.
56. Bruckner V, Kovacs J, Denes G. 1953. Structure of poly-D-glutamic acid isolated from capsulated strains of B. anthracis. Nature 172:508.
57. Richter GS, Anderson VJ, Garufi G, Lu L, Joachimiak A, He C, Schneewind O, Missiakas D. 2009. Capsule anchoring in Bacillus anthracis occurs by a transpeptidation mechanism that is inhibited by capsidin. Mol. Microbiol. 71:404-420.
58. Zwartouw HT, Smith H. 1956. Polyglutamic acid from Bacillus anthracis grown in vivo: structure and aggressin activity. Biochem. J. 63:437-454.
59. Friedlander A. 1986. Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J. Biol. Chem. 261:7123-7126.
60. Petosa C, Collier RJ, Klimpel KR, Leppla SH, Liddington RC. 1997. Crystal structure of the anthrax toxin protective antigen. Nature 385:833-838.